MedTrace Logo

Molar Potency Study of HM12460A in Healthy Subjects

NCT03330314 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2020-08-12

No results posted yet for this study

Summary

This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

HM12460A

HM12460A is a long-acting insulin

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-24
Primary Completion
2018-02-08
Completion
2018-02-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03330314 on ClinicalTrials.gov